Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones.
High-throughput screening of a National Cancer Institute library of pure natural products identified the hydroxylated tropolone derivatives beta-thujaplicinol (2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one) and manicol (1,2,3,4-tetrahydro-5-7-dihydroxy-9-methyl-2-(1-methylethenyl)-6H-benzocyclohepten-6-one) as potent and selective inhibitors of the ribonuclease H (RNase H) activity of human immunodeficiency virus-type 1 reverse transcriptase (HIV-1 RT). beta-Thujaplicinol inhibited HIV-1 RNase H in vitro with an IC50 of 0.2 microM, while the IC50 for Escherichia coli and human RNases H was 50 microM and 5.7 microM, respectively. In contrast, the related tropolone analog beta-thujaplicin (2-hydroxy-4-(methylethyl)-2,4,6-cycloheptatrien-1-one), which lacks the 7-OH group of the heptatriene ring, was inactive, while manicol, which possesses a 7-OH group, inhibited HIV-1 and E.coli RNases H with IC50 = 1.5 microM and 40 microM, respectively. Such a result highlights the importance of the 2,7-dihydroxy function of these tropolone analogs, possibly through a role in metal chelation at the RNase H active site. Inhibition of HIV-2 RT-associated RNase H indirectly indicates that these compounds do not occupy the nonnucleoside inhibitor-binding pocket in the vicinity of the DNA polymerase domain. Both beta-thujaplicinol and manicol failed to inhibit DNA-dependent DNA polymerase activity of HIV-1 RT at a concentration of 50 microM, suggesting that they are specific for the C-terminal RNase H domain, while surface plasmon resonance studies indicated that the inhibition was not due to intercalation of the analog into the nucleic acid substrate. Finally, we have demonstrated synergy between beta-thujaplicinol and calanolide A, a nonnucleoside inhibitor of HIV-1 RT, raising the possibility that both enzymatic activities of HIV-1 RT can be simultaneously targeted.
Budihas
Scott R
SR
Resistance Mechanisms Laboratory, HIV Drug Resistance Program, National Cancer Institute at Frederick Frederick, MD 21702, USA.
Gorshkova
Inna
I
Gaidamakov
Sergei
S
Wamiru
Antony
A
Bona
Marion K
MK
Parniak
Michael A
MA
Crouch
Robert J
RJ
McMahon
James B
JB
Beutler
John A
JA
Le Grice
Stuart F J
SF
D019380:Anti-HIV Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001567:Benzocycloheptenes / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites; D003374:Coumarins / Q000378:metabolism / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D039681:Pyranocoumarins; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D016914:Ribonuclease H / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014334:Tropolone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*
D019380:Anti-HIV Agents; D001567:Benzocycloheptenes; D003374:Coumarins; D039681:Pyranocoumarins; D018894:Reverse Transcriptase Inhibitors; C497842:beta-thujaplicinol; C497843:manicol; D014334:Tropolone; D016914:Ribonuclease H; C075959:calanolide A
Eur J Biochem. 1981 Mar 16;115(1):207-16
7227366
Chembiochem. 2004 Apr 2;5(4):527-33
15185377
Adv Enzyme Regul. 1984;22:27-55
6382953
J Antibiot (Tokyo). 1988 Jul;41(7):862-8
3417559
J Chromatogr. 1988 Nov 25;455:430-3
3235623
J Gen Virol. 1991 Jan;72 ( Pt 1):59-66
1703563
Science. 1991 Apr 5;252(5002):88-95
1707186
J Med Chem. 1992 Jul 24;35(15):2735-43
1379639
J Virol. 1993 Apr;67(4):2412-20
7680393
J Biol Chem. 1994 Mar 25;269(12):8803-7
8132614
Bioorg Med Chem. 1994 Mar;2(3):169-79
7522907
J Biol Chem. 1995 Mar 3;270(9):4861-9
7533167
Biochemistry. 1996 Feb 13;35(6):1911-7
8639674
Biochemistry. 1997 Mar 18;36(11):3179-85
9115994
Antiviral Res. 1998 Aug;39(2):89-100
9806486
Biochemistry. 1999 Oct 5;38(40):13070-6
10529177
Anal Biochem. 2004 Aug 15;331(2):296-302
15265735
Chem Pharm Bull (Tokyo). 2000 Feb;48(2):194-200
10705503
J Biol Inorg Chem. 2000 Feb;5(1):67-74
10766438
Biol Pharm Bull. 2000 Aug;23(8):995-7
10963310
Adv Pharmacol. 2000;49:67-109
11013761
Biochemistry. 2000 Nov 21;39(46):14279-91
11087377
Methods Mol Biol. 2001;160:335-54
11265294
Anal Biochem. 2001 Apr 15;291(2):198-206
11401293
Phytother Res. 2001 Nov;15(7):586-8
11746838
J Biol Chem. 2002 May 10;277(19):16689-96
11875059
Biol Pharm Bull. 2002 Aug;25(8):981-5
12186430
J Biol Chem. 2003 Jan 31;278(5):2777-80
12480948
AIDS Rev. 2002 Oct-Dec;4(4):183-94
12555693
Mol Cell. 2003 Mar;11(3):807-15
12667461
Nucleic Acids Res. 2003 Oct 1;31(19):5776-88
14500841
Biol Pharm Bull. 2003 Oct;26(10):1487-90
14519960
Nucleic Acids Res. 2003 Dec 1;31(23):6852-9
14627818
Anal Biochem. 2003 Nov 1;322(1):33-9
14705777
Anticancer Res. 2003 Nov-Dec;23(6C):4757-63
14981923
Nucleic Acids Res. 2004;32(4):1539-47
15004241
Methods Enzymol. 1982;87:500-9
6757651